A recent study estimates if ASFV reached the United States it could result in economic losses exceeding $50 billion over a ten-year period.

Federal officials cited the end of the Covid-19 pandemic in halting the research. But much of the work was focused on ...

R&D Expenses: Research and development expenses for the year ended December 31, 2024 decreased to approximately $2,044,000 compared to $3,297,000 for the year ended December 31, 2023. The decrease was ...

The EU is introducing new regulations (EDIRPA and EDIP) to structure military procurement through pooled orders coordinated by the ...

EVM14 received FDA clearance for clinical trials, marking Everest Medicines’ first in-house developed therapeutic to reach ...

RNA cancer vaccines are at the forefront of next-generation cancer immunotherapy, showcasing significant potential.

Net Loss: The net loss attributable to Serina for the year ended December 31, 2024 was $11.1 million, or $ (1.51) per basic and diluted share, compared to net income of $5.3 million, or $2.36 per ...

First and only immunotherapy to show meaningful overall survival benefit in a Phase 2 trial in patients with advanced ovarian cancer Initiation ...

EVM14 received U.S. FDA clearance for its IND application, becoming Everest's first internally discovered program, and the first mRNA therapeutic cancer vaccine to be cleared for global clinical ...

AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine company, published an announcement on March 23, 2025, the company's independently developed mRNA shingles vaccine has recently received clinical ...

Researchers have identified antibodies that could lead to a broadly protective norovirus vaccine and new treatment options.

Initiated Phase 1 clinical trial evaluating its second-generation oral norovirus vaccine constructs with topline data expected as early as ...